生产企业：AN2 Therapeutics, Inc.
AN-15368 (also known as AN2-502998 / AN2 502998) is an orally bioavailable, boron-containing heterocyclic small molecule being developed by AN2 Therapeutics. It is a prodrug activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway, acting as a CPSF3 inhibitor. It is under development for Chagas disease (Trypanosoma cruzi infection).
AN-15368 (also known as AN2-502998 / AN2 502998) is an orally bioavailable, boron-containing heterocyclic small molecule being developed by AN2 Therapeutics. It is a prodrug activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway, acting as a CPSF3 inhibitor. It is under development for Chagas disease (Trypanosoma cruzi infection).
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
